HX-009 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This HX-009 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether HX-009 can convert its Bispecific antibody, Antibody fusion proteins profile and PD-1 x SIRPα biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | HX-009 (query alias: HX-009) |
|---|---|
| Modality / target | Bispecific antibody, Antibody fusion proteins; PD-1 x SIRPα; PD-1 inhibitors, SIRPα inhibitors |
| Highest global status | Phase 2 |
| Originator | Wuhan Hanxiong Biotech,inc. |
| Active developers | Hangzhou Hansi Biological Pharmaceutical Co., Ltd. |
The MCP disease footprint includes Biliary Tract Neoplasms, Melanoma, Advanced Malignant Solid Neoplasm. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06708663 | Phase 1/2 | Recruiting | 124 | Primary endpoint not disclosed in English source |
| NCT05731752 | Phase 1 | Unknown status | 80 | Primary endpoint not disclosed in English source |
| NCT05189093 | Phase 1/2 | Completed | 48 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A phase 1b study investigating the safety, tolerability and preliminary efficacy of HX009 in post-immune checkpoint inhibitor (CPI) therapy advanced melanoma patients.
Phase 1; n=19; evaluation: Positive. Reported fields: ORR = 17.6 %
1741A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV+Non-Hodgkin Lymphoma (NHL)
Phase 1/2; n=14; evaluation: Positive. Reported fields: AE = 35.7 %
First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.
Phase 1; n=21; evaluation: Positive. Reported fields: cAE = The most frequent treatment-related AEs include nausea (n = 2, G1), rash (n = 2, G1), vomiting (n = 2, G1), and decreased appetite (n = 2, G1).
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
HX-009 addresses Biliary Tract Neoplasms, Melanoma, Advanced Malignant Solid Neoplasm. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody, Antibody fusion proteins—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 282 matched transaction record(s) under the scope “target-level comparable: PD-1 x SIRPα.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PD-1 x SIRPα records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-09-03 | Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US | Phase 3 | Financial terms not disclosed |
| 2026-07-30 | Curocell partners with Biruni to seek Türkiye approval for RIMQARTO in 2027 | Approved | Financial terms not disclosed |
| 2026-06-30 | Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market | Unknown | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods and compositions for treating cancer using targeted PORE-forming agents”. The milestone feed surfaced a patent-application signal described as “Il-18BP antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Combination of macrophage-directed immunotherapy and cytokines for treatment of cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
